BillionToOne (BLLN) Stock Overview
A precision diagnostics company, quantifies biology to create molecular diagnostics. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
BLLN Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
BillionToOne, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$104.59 |
| 52 Week High | US$138.70 |
| 52 Week Low | US$61.96 |
| Beta | 0 |
| 1 Month Change | 30.90% |
| 3 Month Change | 42.28% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -3.99% |
Recent News & Updates
BillionToOne - Starting 2026 Strong
Summary BillionToOne delivered 84% YoY Q1 sales growth, driven by prenatal and oncology clinical testing segments. BillionToOne raised full-year revenue guidance to $450–$465 million, reflecting strong demand, pricing, and volume momentum. GAAP operating profit reached $17.8 million, demonstrating operating leverage and margin expansion amid declining pricing pressure. New product launches like Unity Confirm and oncology diversification reinforce BillionToOne's platform superiority and support a positive growth outlook. Read the full article on Seeking AlphaBillionToOne's (NASDAQ:BLLN) Earnings May Just Be The Starting Point
BillionToOne, Inc.'s ( NASDAQ:BLLN ) strong earnings report was rewarded with a positive stock price move. We have done...Recent updates
Shareholder Returns
| BLLN | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 6.9% | 2.2% | -0.1% |
| 1Y | n/a | 17.0% | 26.3% |
Return vs Industry: Insufficient data to determine how BLLN performed against the US Healthcare industry.
Return vs Market: Insufficient data to determine how BLLN performed against the US Market.
Price Volatility
| BLLN volatility | |
|---|---|
| BLLN Average Weekly Movement | 12.9% |
| Healthcare Industry Average Movement | 7.2% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BLLN's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: BLLN's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 713 | Oguzhan Atay | www.billiontoone.com |
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It also offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and types of mutations detected that include deletions, insertions, and point mutations; and Northstar Response, a methylation-based assay that quantifies the amount of cancer at the single molecule level without requiring a tissue biopsy, enabling real-time monitoring of patient response to therapy with unprecedented precision.
BillionToOne, Inc. Fundamentals Summary
| BLLN fundamental statistics | |
|---|---|
| Market cap | US$4.52b |
| Earnings (TTM) | US$24.88m |
| Revenue (TTM) | US$354.54m |
Is BLLN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BLLN income statement (TTM) | |
|---|---|
| Revenue | US$354.54m |
| Cost of Revenue | US$104.96m |
| Gross Profit | US$249.58m |
| Other Expenses | US$224.71m |
| Earnings | US$24.88m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.54 |
| Gross Margin | 70.40% |
| Net Profit Margin | 7.02% |
| Debt/Equity Ratio | 17.8% |
How did BLLN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/04 09:00 |
| End of Day Share Price | 2026/06/04 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BillionToOne, Inc. is covered by 9 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mark Massaro | BTIG |
| Subhalaxmi Nambi | Guggenheim Securities, LLC |
| Tycho Peterson | Jefferies LLC |